Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19

doi:10.1016/j.cell.2020.08.025

. 2020 Oct 1;183(1):143-157.e13.

doi: 10.1016/j.cell.2020.08.025. Epub 2020 Aug 19.

Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19

Naoki Kaneko¹, Hsiao-Hsuan Kuo¹, Julie Boucau¹, Jocelyn R Farmer¹, Hugues Allard-Chamard², Vinay S Mahajan³, Alicja Piechocka-Trocha⁴, Kristina Lefteri¹, Matthew Osborn¹, Julia Bals¹, Yannic C Bartsch¹, Nathalie Bonheur¹, Timothy M Caradonna¹, Josh Chevalier¹, Fatema Chowdhury¹, Thomas J Diefenbach¹, Kevin Einkauf¹, Jon Fallon¹, Jared Feldman¹, Kelsey K Finn¹, Pilar Garcia-Broncano¹, Ciputra Adijaya Hartana¹, Blake M Hauser¹, Chenyang Jiang¹, Paulina Kaplonek¹, Marshall Karpell¹, Eric C Koscher¹, Xiaodong Lian¹, Hang Liu¹, Jinqing Liu¹, Ngoc L Ly¹, Ashlin R Michell¹, Yelizaveta Rassadkina¹, Kyra Seiger¹, Libera Sessa¹, Sally Shin¹, Nishant Singh¹, Weiwei Sun¹, Xiaoming Sun¹, Hannah J Ticheli¹, Michael T Waring⁴, Alex L Zhu¹, Galit Alter¹, Jonathan Z Li⁵, Daniel Lingwood¹, Aaron G Schmidt⁶, Mathias Lichterfeld⁷, Bruce D Walker⁸, Xu G Yu⁷, Robert F Padera Jr⁹, Shiv Pillai¹⁰; Massachusetts Consortium on Pathogen Readiness Specimen Working Group

Affiliations

¹ Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
² Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Division of Rheumatology, Faculté de Médecine et des Sciences de la Santé de l'Université de Sherbrooke et Centre de Recherche Clinique Étienne-Le Bel, Sherbrooke, QC J1K 2R1, Canada.
³ Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
⁴ Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
⁵ Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
⁶ Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Department of Microbiology, Harvard Medical School, Boston, MA 02115, USA.
⁷ Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
⁸ Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA; Department of Biology and Institute of Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
⁹ Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA. Electronic address: rpadera@bwh.harvard.edu.
¹⁰ Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA. Electronic address: pillai@helix.mgh.harvard.edu.

PMID: 32877699
PMCID: PMC7437499
DOI: 10.1016/j.cell.2020.08.025

Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19

Naoki Kaneko et al. Cell. 2020.

. 2020 Oct 1;183(1):143-157.e13.

doi: 10.1016/j.cell.2020.08.025. Epub 2020 Aug 19.

Authors

Affiliations

¹ Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
² Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Division of Rheumatology, Faculté de Médecine et des Sciences de la Santé de l'Université de Sherbrooke et Centre de Recherche Clinique Étienne-Le Bel, Sherbrooke, QC J1K 2R1, Canada.
³ Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
⁴ Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
⁵ Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
⁶ Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Department of Microbiology, Harvard Medical School, Boston, MA 02115, USA.
⁷ Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
⁸ Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA; Department of Biology and Institute of Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
⁹ Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA. Electronic address: rpadera@bwh.harvard.edu.
¹⁰ Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA. Electronic address: pillai@helix.mgh.harvard.edu.

PMID: 32877699
PMCID: PMC7437499
DOI: 10.1016/j.cell.2020.08.025

Abstract

Humoral responses in coronavirus disease 2019 (COVID-19) are often of limited durability, as seen with other human coronavirus epidemics. To address the underlying etiology, we examined post mortem thoracic lymph nodes and spleens in acute SARS-CoV-2 infection and observed the absence of germinal centers and a striking reduction in Bcl-6⁺ germinal center B cells but preservation of AID⁺ B cells. Absence of germinal centers correlated with an early specific block in Bcl-6⁺ T_FH cell differentiation together with an increase in T-bet⁺ T_H1 cells and aberrant extra-follicular TNF-α accumulation. Parallel peripheral blood studies revealed loss of transitional and follicular B cells in severe disease and accumulation of SARS-CoV-2-specific "disease-related" B cell populations. These data identify defective Bcl-6⁺ T_FH cell generation and dysregulated humoral immune induction early in COVID-19 disease, providing a mechanistic explanation for the limited durability of antibody responses in coronavirus infections, and suggest that achieving herd immunity through natural infection may be difficult.

Keywords: COVID-19; SARS-CoV-2; T follicular helper cells; TNF-α; cytokine dysregulation; double-negative B cells; extra-follicular B cells; germinal centers; humoral immunity; plasmablasts.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interests S.P. is on the SAB of Abpro Inc. and Pulsar Biopharma. G.A. is founder of Seromyx Systems Inc.

Figures

**Figure 1**
Early Loss of Germinal Centers and Bcl-6-Expressing B Cells in COVID-19 Thoracic Lymph Nodes (A) Hematoxylin-eosin staining of lymph nodes from early (left) and late (right) COVID-19 patients. (B) Low-power images of CD3 (red), CD19 (green), Bcl-6 (orange), and DAPI (blue) staining in a lymph node from a late COVID-19 patient (left) and a non-COVID-19 thoracic lymph node (right). (C) Representative multi-color immunofluorescence images of CD3 (red), CD19 (green), Bcl-6 (orange), and AID (purple) staining in lymph nodes from early (left) and late (middle) COVID-19 patients and a non-COVID-19 lymph node (right). (D and E) Absolute numbers of CD19⁺ B cells (D) and CD3⁺ T cells (E) in lymph nodes from COVID-19 patients (purple, n = 11) and non-COVID-19 patients (blue, n = 6). COVID-19 samples include early (purple, n = 5) and late (red, n = 6) COVID-19 patients. (F and G) Absolute numbers and relative proportion of Bcl6⁺ B cells (F) and AID⁺ B cells (G) in the pool of CD19⁺ B cells in lymph nodes from COVID-19 patients (purple, n = 11) and non-COVID-19 patients (blue, n = 6). COV-19, COVID-19; LN, lymph node. Mann-Whitney U test was used to calculate p value. Error bars represent mean ± SEM. ^∗∗p < 0.01; ^∗∗∗p < 0.001. See also Figure S1 and Tables S1 and S2.

**Figure 2**
White Pulp Attrition, Early Loss of Germinal Centers, and Bcl-6-Expressing B Cells in COVID-19 Spleens (A) Cross-sectional view of whole spleen and hematoxylin-eosin staining from early (left) and late (right) COVID-19 patients. (B) Low-power images of CD3 (red), CD19 (green), Bcl-6 (orange), and DAPI (blue) staining in a spleen from a late COVID-19 patient (left) and a control (right). (C) Representative multi-color immunofluorescence image of CD3 (red), CD19 (green), Bcl-6 (orange), and AID (purple) staining in spleens from a late COVID-19 patient (left) and a control (right). (D and E) Absolute numbers of CD19⁺ B cells (D) and CD3⁺ T cells (E) in spleens from early (purple, n = 4) and late (red, n = 6) COVID-19 patients and controls (blue, n = 7). (F and G) Absolute numbers and relative proportion of Bcl-6⁺ B cells (F) and AID⁺ B cells (G) in spleens from early (purple, n = 4) and late (red, n = 6) COVID-19 patients and controls (blue, n = 7). SP, spleen. Multiple comparisons are controlled for by Kruskal-Wallis test. Error bars represent mean ± SEM. ^∗p < 0.05. See also Tables S2 and S3.

**Figure S1**
FDCs Are Not Lost in COVID-19 Lymph Nodes, Related to Figure 1 Representative multi-color immunofluorescence images of CD19 (red), Bcl6 (white), CD35 (green) and DAPI (blue) staining in lymph nodes from late COVID-19 patient (lower panel) and controls (upper panels).

**Figure 3**
Loss of Germinal Center Type Bcl-6⁺ T Follicular Helper Cells in COVID-19 Lymph Nodes and Spleens (A) Representative multi-color immunofluorescence image of CD4 (red), ICOS (green), and DAPI (blue) staining in lymph nodes from early (left) and late (middle) COVID-19 patients and a non-COVID-19 control (right). Arrows indicate CD4⁺ ICOS⁺ T_FH cells. (B) Representative multi-color immunofluorescence images of CD4 (red), Bcl-6 (white), and DAPI (blue) staining in lymph nodes from early (left) and late (middle) COVID-19 patients and a non-COVID-19 control (right). Arrows indicate CD4⁺ Bcl6⁺ GC-type T_FH cells. (C) Representative multi-color immunofluorescence images of CD4 (red), ICOS (green), and DAPI (blue) staining in spleens from early (left) and late (middle) COVID-19 patients and a control (right). (D) Representative multi-color immunofluorescence images of CD4 (red), Bcl-6 (white), and DAPI (blue) staining in spleens from early (left) and late (middle) COVID-19 patients and a control (right). (E and F) Absolute numbers and relative proportions of CD4⁺ ICOS⁺ T_FH cells (E) and CD4⁺ Bcl-6⁺ GC-type T_FH cells (F) in lymph nodes from COVID-19 patients (purple, n = 11) and non-COVID-19 patients (blue, n = 6). COVID-19 samples include early (purple, n = 5) and late (red, n = 6) COVID-19 patients. (G and H) Relative proportions of CD4⁺ ICOS⁺ T_FH cells (G) and CD4⁺ Bcl-6⁺ GC-type T_FH (H) in spleens from COVID-19 patients (purple, n = 10) and controls (blue, n = 7). COVID-19 samples include early (purple, n = 4) and late (red, n = 6) COVID-19 patients. Mann-Whitney U test used to calculate p value. Error bars represent mean ± SEM. ^∗p < 0.05; ^∗∗p < 0.01; ^∗∗∗p < 0.001. See also Figures S2, S3, and S4 and Tables S1, S2, and S3.

**Figure S2**
Decrease in CXCR5⁺ T Follicular Helper Cells in COVID-19 Lymph Nodes and Spleens, Related to Figure 3 (A) Representative multi-color immunofluorescence images of CD4 (red), CXCR5 (green) and DAPI (blue) staining in lymph nodes from early (left) and late (middle) COVID-19 patients and a non-COVID-19 lymph node (right). Arrows indicate CD4⁺ CXCR5⁺ T_FH cells. (B) Representative multi-color immunofluorescence images of CD4 (red), CXCR5 (green) and DAPI (blue) staining in spleens from early (left) and late (middle) COVID-19 patients and a control (right). (C and D) Absolute numbers (C) and relative proportions (D) of CD4⁺ CXCR5⁺ T_FH cells in lymph nodes and spleens from COVID-19 patients and non-COVID-19 lymph nodes (blue) (n = 6) and control spleens (blue) (n = 7). COVID-19 samples include early (purple; lymph node; n = 5) (spleen; n = 4) and late (red dots) (n = 6) COVID-19 patients. Mann-Whitney U test used to calculate p value. Error bars represent mean ± SEM. ^∗∗p < 0.01; ^∗∗∗p < 0.001.

**Figure S3**
Increased T reg Cells but No Differentiation into TFR Cells in COVID-19 Lymph Nodes, Related to Figure 3 (A) Representative multi-spectral 7 color immunofluorescence images showing CD4 (red), CD19 (green), CXCR5 (purple), Bcl6 (white), FoxP3 (yellow), IgG (light blue) and DAPI (blue) staining of lymph nodes from late COVID-19 patients. Images in the green box show high-power images. No FoxP3⁺/Bcl6⁺ cells were seen (white staining with no yellow overlap) in follicles. (B) IgG⁺ plasmablasts are found in follicular and extra-follicular areas in COVID-19 lymph nodes. Related to Figure 3. Representative multi-color immunofluorescence images of Bcl6 (white) and IgG (light blue) in lymph nodes of a late COVID-19 patient (left) and a control (right). IgG⁺ cells were abundant in follicular and extrafollicular areas in both COVID-19 lymph nodes and controls. (C and D) Large increase in TNF-α production at both follicular and extra-follicular sites in COVID-19 lymph nodes, while controls have low levels of TNF-α localized to follicles. Related to Figure 3. (C) Representative multi-color immunofluorescence images of TNF-α (green) and DAPI (blue) staining in lymph nodes from early and late COVID-19 patients and a control. (D) Absolute numbers (left) and percentages (right) of TNF-α+ cells in lymph nodes from early (purple) (n = 5) and late (red; n = 6) COVID-19 patients and controls (blue; n = 10). Multiple comparisons were controlled for by Kruskal-Wallis test. Error bars represent mean ± SEM. ^∗p < 0.05; ^∗∗p < 0.01.

**Figure 4**
T_H1 Cells Are Expanded in Comparison to Other CD4⁺ T Cell Subsets in COVID-19 Thoracic Lymph Nodes and Spleens (A) Representative multi-color staining showing T_H1, T_H2, T_H17, and T reg cells in lymph nodes form early (left) and late (middle) COVID-19 patients and a non-COVID-19 control (right; T_H1: CD4⁺ [red] T-bet⁺ [light blue]; T_H2: CD4⁺ [red] GATA3⁺ [purple]; T_H17: CD4⁺ [red] RORγ⁺ [yellow]; T reg cell: CD4⁺ [red] FOXP3⁺ [green]). (B) Absolute numbers and relative proportions of T_H1, T_H2, T_H17, and T reg cells in lymph nodes and spleens (purple) from early (purple, lymph nodes: n = 5; spleens: n = 4) and late (red, n = 6) COVID-19 patients and controls (blue, lymph nodes: n = 6; spleens: n = 7). Mann-Whitney U test was used to calculate p value. Error bars represent mean ± SEM. ^∗p < 0.05; ^∗∗p < 0.01. See also Figures S5, S6, and S7 and Tables S1, S2, and S3.

**Figure S4**
Increase in CD4⁺/CD8⁺ T Cell Ratio in Lymph Nodes and Spleens in COVID-19, Related to Figure 4 (A) Representative multi-color immunofluorescence images of CD4 (red), CD8 (green) and DAPI (blue) staining in lymph nodes (top 2 rows of images) and spleens (bottom 2 rows of pictures) from early (left) and late (middle) COVID-19 patients and controls (right). (B) Relative ratios of CD4 and CD8 T cells (No./mm²) in lymph nodes (left) and spleens (right) from early (purple) (n = 5/4) and late (red) (n = 6) COVID-19 patients and controls (blue) (n = 10/7).

**Figure S5**
Follicular and Extra-follicular T-B Conjugates and IgD⁻CD27⁻ B Cells in COVID-19 Lymph Nodes, Related to Figure 4 (A) Immunofluorescence staining of CD3 (red), CD19 (green) and DAPI (blue) in a lymph node (top) and a spleen (bottom) in a late COVID-19 patient. Arrows and arrowheads indicate CD3⁺ T cells and CD19⁺ B cells respectively. T cell and B cells formed close and extensive intercellular plasma membrane contacts as highlighted in the yellow box. (B) Immunofluorescence staining (left panels) and visualization of T-B conjugates (middle and right panels) in a lymph node from a late COVID-19 patient using the StrataQuest cell-to-cell contact application. Masks of the nuclei based on DAPI staining establish the inner boundary of the cytoplasm and the software “looks” outward toward the plasma membrane boundary. An overlap of at least 3 pixels of adjacent cell markers was required to establish each “contact” criterion. Details are in the STAR Methods section. Nuclei circled in red and green respectively depict CD3⁺ T cells and CD19⁺ B cells in T-B conjugates. Each box (purple, light blue and yellow) highlights a T-B conjugate. (C) Representative multi-color immunofluorescence image of CD19 (red), IgD and CD27 (both in green) and DAPI (blue) staining in a lymph node from an early COVID-19 patient. IgD^-/CD27^- double negative B cells (red staining with no green overlap) are abundant inside the follicle and also outside. Boxed area depicts some of these cells outside the follicle. White arrows show IgD^-/CD27^- double negative B cells.

**Figure 5**
Decreased Early Transitional and Follicular B Cells in the Peripheral Blood of Patients with Severe COVID-19 (A and B) Quantitation of (A) total CD19⁺ B cells and (B) naive, early transitional (T1/2), and follicular (FO) B cell subsets in the peripheral blood of patients with COVID-19 at states of convalescence (n = 39), severe illness with an intermediate maximum CRP level during hospitalization (<200 mg/L; severe [CRP int]; n = 10), and severe illness with a high maximum CRP level during hospitalization (>200 mg/L; severe [CRP hi]; n = 15) as defined by the clinical criteria listed in Table S4 and compared to healthy controls (n = 4). Quantitation is shown by B cell level for each individual patient with mean, standard deviation, and significance by one-way ANOVA of log % B cell value indicated (^∗p < 0.05; ^∗∗p < 0.01; ^∗∗∗p < 0.001; ^∗∗∗∗p < 0.0001). Representative COVID-19 contour plots shown (B) with healthy control contour plots and full B cell flow cytometry gating strategy outlined (Figure S6). (C and D) Association of peripheral blood B cell frequency with maximum CRP level (C) and the clinical parameters of symptom duration at blood draw and total length of hospital stay (D) in all symptomatic COVID-19 patients (n = 29) with moderate to severe illness as defined by the clinical criteria listed in Table S4. Correlation is shown by linear regression with individual patients, 95% confidence bands, R², and p values shown. See also Figures S6 and S7 and Table S4.

**Figure S6**
Analysis of Circulating B Cell Subsets by Flow Cytometry, Related to Figures 5, 6, and 7 (A) Gating strategy for COVID-19 PBMCs. (B) Representative flow plots of relevant B cell subsets from PBMCs derived from a healthy donor. Antibody-secreting (Ab-secreting), double negative (DN), follicular (FO), marginal zone precursor (MZP), switched memory (SM), transitional (T), unswitched memory (USM).

**Figure 6**
Increased Proportions of Activated B Cell Subsets in the Peripheral Blood of Patients with Severe COVID-19 (A–E) Proportions of (A) switched memory (SM) B cells, (B) plasmablasts, (C) activated naive and CXCR5-late transitional (T3a) B cells, (D) IgD⁻CD27⁻ double-negative (DN) B cells, and (E) total (sum) activated B cells in the peripheral blood of patients with COVID-19 at states of convalescence (n = 39), severe illness with an intermediate maximum CRP level during hospitalization (<200 mg/L; severe CRP int; n = 10), and severe illness with a high maximum CRP level during hospitalization (>200 mg/L; severe CRP hi; n = 15), as defined by the clinical criteria listed in Table S4 and compared to healthy controls (n = 4). Quantitation is shown by B cell level for each individual patient with mean, standard deviation, and significance by one-way ANOVA of log % B cell value indicated (^∗p < 0.05; ^∗∗p < 0.01; ^∗∗∗p < 0.001; ^∗∗∗∗p < 0.0001). Representative COVID-19 contour plots are shown with healthy control contour plots and full B cell flow cytometry gating strategy outlined (Figure S6). (F) Association of activated B cell frequency in peripheral blood with maximum CRP level, symptom duration at blood draw, and total length of hospital stay in all symptomatic COVID-19 patients (n = 29) with moderate to severe illness as defined by the clinical criteria listed in Table S4. Correlation is shown by linear regression with individual patients, 95% confidence bands, R², and p values shown. See also Figures S6 and S7 and Table S4.

**Figure S7**
Quantitation of B Cells, Related to Figures 5 and 6 Quantitation of absolute B cell counts was undertaken in all COVID-19 patients in whom a proximal absolute lymphocyte count (ALC) was available in the electronic medical record at states of convalescence (n = 5), severe illness with an intermediate maximum CRP level during hospitalization (< 200 mg/L; severe (CRP int); n = 10), and severe illness with a high maximum CRP level during hospitalization (> 200 mg/L; severe (CRP hi); n = 15) as defined by the clinical criteria listed in Table S4. Data are compared to healthy controls (n = 4), assuming a healthy control ALC of 2.9 (K/uL). Quantitation shown by B cell level for each individual patient with mean, standard deviation, and significance by one-way ANOVA of log % B cell value indicated (^∗p < 0.05, ^∗∗p < 0.01, ^∗∗∗p < 0.001) for (A) total CD19⁺ B cells, (B) naive, early transitional (T1/2), and follicular (FO) B cell subsets, (C) activated and double negative (DN) B cell subsets as indicated, and (D) activated and DN B cell subsets as a ratio to the available precursor population (naive, IgD⁺CD27^-).

**Figure 7**
Activated B Cell Subsets in the Peripheral Blood of Patients with COVID-19 Are Specific for SARS-CoV-2-RBD (A) Representative dot plots showing positive SARS-CoV-2-RBD staining in total CD19⁺ B cells (left; boxed in red) and B cell subsets (right; colored in red). (B) All CD19⁺ B cells binding to SARS-CoV-2-RBD shown for COVID-19 patients at states of convalescence (n = 10) and severe illness (n = 4) with summation of total % CoV-2-RBD reactivity by indicated B cell subset and quantitated as mean ± SD with significance by Student’s t test of log % B cell value indicated (^∗p < 0.05). DN2 and DN3 double-negative B cells are CXCR5 low, although DN1 and DN4 B cells are CXCR5 high. Ab-secreting, antibody secreting; DN, double-negative; MZP, marginal zone precursor; SM, switched memory; T, transitional; USM, unswitched memory. Ab-secreting cells included both plasmablasts and plasma cell, though the latter were very rare. See also Figure S6 and Table S4.

See this image and copyright information in PMC

Update of

The Loss of Bcl-6 Expressing T Follicular Helper Cells and the Absence of Germinal Centers in COVID-19.
Kaneko N, Kuo HH, Boucau J, Farmer JR, Allard-Chamard H, Mahajan VS, Piechocka-Trocha A, Lefteri K, Osborn M, Bals J, Bartsch YC, Bonheur N, Caradonna TM, Chevalier J, Chowdhury F, Diefenbach TJ, Einkauf K, Fallon J, Feldman J, Finn KK, Garcia-Broncano P, Hartana CA, Hauser BM, Jiang C, Kaplonek P, Karpell M, Koscher EC, Lian X, Liu H, Liu J, Ly NL, Michell AR, Rassadkina Y, Seiger K, Sessa L, Shin S, Singh N, Sun W, Sun X, Ticheli HJ, Waring MT, Zhu AL, Li J, Lingwood D, Schmidt AG, Lichterfeld M, Walker BD, Yu X, Padera RF Jr, Pillai S; Massachusetts Consortium on Pathogen Readiness Specimen Working Group. Kaneko N, et al. SSRN [Preprint]. 2020 Jul 16:3652322. doi: 10.2139/ssrn.3652322. SSRN. 2020. Update in: Cell. 2020 Oct 1;183(1):143-157.e13. doi: 10.1016/j.cell.2020.08.025 PMID: 32742244 Free PMC article. Updated. Preprint.

Comment in

COVID-19 Makes B Cells Forget, but T Cells Remember.
Cañete PF, Vinuesa CG. Cañete PF, et al. Cell. 2020 Oct 1;183(1):13-15. doi: 10.1016/j.cell.2020.09.013. Epub 2020 Sep 4. Cell. 2020. PMID: 32976799 Free PMC article.

Cited by

Longitudinal characterization of circulating neutrophils uncovers phenotypes associated with severity in hospitalized COVID-19 patients.
LaSalle TJ, Gonye ALK, Freeman SS, Kaplonek P, Gushterova I, Kays KR, Manakongtreecheep K, Tantivit J, Rojas-Lopez M, Russo BC, Sharma N, Thomas MF, Lavin-Parsons KM, Lilly BM, Mckaig BN, Charland NC, Khanna HK, Lodenstein CL, Margolin JD, Blaum EM, Lirofonis PB, Revach OY, Mehta A, Sonny A, Bhattacharyya RP, Parry BA, Goldberg MB, Alter G, Filbin MR, Villani AC, Hacohen N, Sade-Feldman M. LaSalle TJ, et al. Cell Rep Med. 2022 Oct 18;3(10):100779. doi: 10.1016/j.xcrm.2022.100779. Epub 2022 Sep 26. Cell Rep Med. 2022. PMID: 36208629 Free PMC article.
Association between SARS-CoV-2 RNAemia and dysregulated immune response in acutely ill hospitalized COVID-19 patients.
Rovito R, Bono V, Augello M, Tincati C, Mainoldi F, Beaudoin-Bussières G, Tauzin A, Bianchi S, Hadla M, Yellenki V, d'Arminio Monforte A, Casola S, Borghi E, Finzi A, Marchetti G. Rovito R, et al. Sci Rep. 2022 Nov 16;12(1):19658. doi: 10.1038/s41598-022-23923-1. Sci Rep. 2022. PMID: 36385627 Free PMC article.
COVID-19 immunopathology: From acute diseases to chronic sequelae.
Arish M, Qian W, Narasimhan H, Sun J. Arish M, et al. J Med Virol. 2023 Jan;95(1):e28122. doi: 10.1002/jmv.28122. Epub 2022 Sep 13. J Med Virol. 2023. PMID: 36056655 Free PMC article. Review.
B-Cell Responses to Sars-Cov-2 mRNA Vaccines.
Kardava L, Buckner CM, Moir S. Kardava L, et al. Pathog Immun. 2022 Dec 9;7(2):93-119. doi: 10.20411/pai.v7i2.550. eCollection 2022. Pathog Immun. 2022. PMID: 36655200 Free PMC article. Review.
COVID-19 and plasma cells: Is there long-lived protection?
Nguyen DC, Lamothe PA, Woodruff MC, Saini AS, Faliti CE, Sanz I, Lee FE. Nguyen DC, et al. Immunol Rev. 2022 Aug;309(1):40-63. doi: 10.1111/imr.13115. Epub 2022 Jul 8. Immunol Rev. 2022. PMID: 35801537 Free PMC article. Review.

See all "Cited by" articles

References

1. Amanat F., Stadlbauer D., Strohmeier S., Nguyen T.H.O., Chromikova V., McMahon M., Jiang K., Arunkumar G.A., Jurczyszak D., Polanco J. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 2020;26:1033–1036. - PMC - PubMed
1. Brouwer P.J.M., Caniels T.G., van der Straten K., Snitselaar J.L., Aldon Y., Bangaru S., Torres J.L., Okba N.M.A., Claireaux M., Kerster G. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science. 2020;369:643–650. - PMC - PubMed
1. Buja L.M., Wolf D.A., Zhao B., Akkanti B., McDonald M., Lelenwa L., Reilly N., Ottaviani G., Elghetany M.T., Trujillo D.O. The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities. Cardiovasc. Pathol. 2020;48:107233. - PMC - PubMed
1. Crotty S. T follicular helper cell differentiation, function, and roles in disease. Immunity. 2014;41:529–542. - PMC - PubMed
1. Ecker R.C., Steiner G.E. Microscopy-based multicolor tissue cytometry at the single-cell level. Cytometry A. 2004;59:182–190. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- H1 Connect
- The Lens - Patent Citations Database
Miscellaneous
- NCI CPTAC Assay Portal

[1] Amanat F., Stadlbauer D., Strohmeier S., Nguyen T.H.O., Chromikova V., McMahon M., Jiang K., Arunkumar G.A., Jurczyszak D., Polanco J. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 2020;26:1033–1036. - PMC - PubMed

[2] Amanat F., Stadlbauer D., Strohmeier S., Nguyen T.H.O., Chromikova V., McMahon M., Jiang K., Arunkumar G.A., Jurczyszak D., Polanco J. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 2020;26:1033–1036. - PMC - PubMed

[3] Brouwer P.J.M., Caniels T.G., van der Straten K., Snitselaar J.L., Aldon Y., Bangaru S., Torres J.L., Okba N.M.A., Claireaux M., Kerster G. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science. 2020;369:643–650. - PMC - PubMed

[4] Brouwer P.J.M., Caniels T.G., van der Straten K., Snitselaar J.L., Aldon Y., Bangaru S., Torres J.L., Okba N.M.A., Claireaux M., Kerster G. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science. 2020;369:643–650. - PMC - PubMed

[5] Buja L.M., Wolf D.A., Zhao B., Akkanti B., McDonald M., Lelenwa L., Reilly N., Ottaviani G., Elghetany M.T., Trujillo D.O. The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities. Cardiovasc. Pathol. 2020;48:107233. - PMC - PubMed

[6] Buja L.M., Wolf D.A., Zhao B., Akkanti B., McDonald M., Lelenwa L., Reilly N., Ottaviani G., Elghetany M.T., Trujillo D.O. The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities. Cardiovasc. Pathol. 2020;48:107233. - PMC - PubMed

[7] Crotty S. T follicular helper cell differentiation, function, and roles in disease. Immunity. 2014;41:529–542. - PMC - PubMed

[8] Crotty S. T follicular helper cell differentiation, function, and roles in disease. Immunity. 2014;41:529–542. - PMC - PubMed

[9] Ecker R.C., Steiner G.E. Microscopy-based multicolor tissue cytometry at the single-cell level. Cytometry A. 2004;59:182–190. - PubMed

[10] Ecker R.C., Steiner G.E. Microscopy-based multicolor tissue cytometry at the single-cell level. Cytometry A. 2004;59:182–190. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19

Affiliations

Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Update of

Comment in

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Miscellaneous

Abstract

Conflict of interest statement

Figures

Update of

Comment in

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Miscellaneous